CML drug combo aims for Treatment-Free remission, but trial stalls
NCT ID NCT05413915
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tested whether adding asciminib to the standard drug imatinib could help people with chronic myeloid leukemia (CML) achieve a deep remission and safely stop all medication. Only 8 patients were enrolled before the study was terminated early, making it too small to draw firm conclusions. The goal was to see if the combination could lead to longer periods without relapse after stopping treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
asciminib and imatinib
What this could lead to
If successful, this approach could help some CML patients safely stop taking daily medication while keeping the leukemia under control.
What could go wrong
The trial was terminated early with only 8 participants, so results are very limited. It is unclear if adding asciminib is better than imatinib alone, and there may be side effects from combining two drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Unit - Jewish General Hospital
Montreal, Quebec, H3T1E2, Canada
-
Hôpital Enfant-Jésus - CHUQ
Québec, Quebec, G1J 1Z4, Canada
-
Hôpital Fleurimont - CHUS (CIUSSS Estrie)
Sherbrooke, Quebec, J1H 5N4, Canada
-
Hôpital Maisonneuve-Rosemont (CIUSSS EMTL)
Montreal, Quebec, H1T 2M4, Canada